Trials / Completed
CompletedNCT00037219
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
A Phase 2, Open-Label, Randomized, Dose-Ranging Study of the Safety and Efficacy of Intravenous Anidulafungin (VER002) in the Treatment of Patients With Invasive Candidiasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States patients with invasive candidiasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anidulafungin, VER002 |
Timeline
- Start date
- 2001-08-01
- Completion
- 2002-11-01
- First posted
- 2002-05-17
- Last updated
- 2008-10-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00037219. Inclusion in this directory is not an endorsement.